These findings were reinforced by observations that the knockdown of PGC1induces similar metabolic reprogramming as seen in MITF deficiency in melanoma, and knocking down PFKFB2 significantly reduces glycolytic capacity and leads to tumor regression. Here, PFKFB2 is linked to melanoma.